Better Disease Control by Multidrug Regimen in Scabies

Scabies is associated with significant discomfort and social taboo. Existing treatment regimen frequently fails due to lack of patient compliance. We compared single use regimen to existing standard repeat application regimen for treatment of scabies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Scabies Ectoparasitic Infestations Infections Mite Infestations Parasitic Diseases Skin Diseases Skin Diseases, Infectious Skin Diseases, Parasitic Skin and Connective Tissue Diseases

Age range

5 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Willing patients
Clinical diagnosis of scabies
Within the age limits

Exclusion criteria

Unwilling patients
Patients with severe co-morbidities requiring long term medication
Pregnant women
Patients who don't fulfill the age limit criteria

Treatment and study plan

Permethrin Lotion 5%

Drug

Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.

Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg

Drug

Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.

Primary outcomes

Pruritus

Time frame: 1 month

Rate of relief from pruritus assessed using visual analog scale

Secondary outcomes

Skin lesions

Time frame: 1 month

Rate of eradication of skin lesions assessed using physician global assessment scale

Sponsors and collaborators

Lead sponsor

B.P. Koirala Institute of Health Sciences

Other

Registry information

Official study title

Better Disease Control by Multidrug Regimen in Scabies: A Randomized Controlled Trial

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2018
First posted: Jan 20, 2022
Registry last updated: Jan 20, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed